Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its drug development, particularly for NTLA-3001, which has led to significant stock price declines [4][5]. Group 1: Company Overview - Intellia Therapeutics is a genome editing company focused on developing curative therapeutics [3]. - The company received authorization from the UK's Medicine and Healthcare products Regulatory Agency for a Phase 1/2 study of NTLA-3001 targeting alpha-1 antitrypsin deficiency-associated lung disease on July 30, 2024 [3]. Group 2: Allegations in the Lawsuit - The lawsuit claims that Intellia's management made false or misleading statements about the viability of NTLA-3001's development and marketing potential [4]. - It is alleged that the company provided overly optimistic timelines for drug dosing and future studies, which did not align with reality [4]. - The complaint states that Intellia was not adequately prepared to dose patients with NTLA-3001 or maintain its research and development efforts due to the challenges of viral-based editing methods [4]. - The lawsuit also highlights that even if NTLA-3001 was successful, the use of viral-based editing drugs is costly and inefficient [4]. Group 3: Impact on Stock Price - Following the announcement of a company reorganization on January 9, 2025, which included the discontinuation of NTLA-3001, Intellia's stock price fell by more than 15% [5].